Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Fig. 1

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. First, increased PD-L1 level is an indicator of the pre-existed anti-tumor immune response which is positively correlated to response rate to anti-PD-1/PD-L1 treatment. Second, TIL is the effectors of anti-tumor immune response, which could be boosted by PD-1/PD-L1 inhibitors. Besides, TMB and neoantigens determine cancer immunogenicity which is the basis of anti-tumor response. In addition, multiple other factors such as suppressive immune cells, driver gene mutations, gut microbiota, tumor metabolites such as IDO1 also participate in anti-tumor immunity and affect the efficacy of anti-PD-1/PD-L1 therapies

Back to article page